Investor Presentaiton
Manufacturing Growth Drivers: Capitalizing on the
Rapid Expansion of Biologics and C> Pipelines
Driven by biologics
No competitors have our comprehensive, rapid, and efficient testing platform for
microbial detection and identification
Only 10% of industry-wide endotoxin testing volume converted to rapid testing methods
- long runway for future growth
Increased number of biologics in development, fueled by C> programs
~3,300 C> programs in the biopharma R&D pipeline, with >2/3 of programs in
preclinical phase
Stay abreast of new technologies and initiatives to connect with clients
-
Evolving trend towards next-generation sequencing (NGS) testing technologies
C> CDMO business gaining traction and expected to perform meaningfully
better this year
Leveraging our premier position in this high-growth market sector for advanced modalities
Several clients moving towards commercialization after completed regulatory audits
Charles River Laboratories (CRL)
13View entire presentation